JDD Buzz Series | AI in Dermatology Residency Applications
AI in dermatologyThe use of artificial intelligence (AI) programs such as ChatGPT is a source of controversy in academia, including in the college admissions process. Are applicants for dermatology residency programs using AI to write or enhance their personal statements, and if so, to what extent? A study published in the May Journal of Drugs in Dermatology found a significant increase in AI usage in dermatology …
AI in dermatology
JDD Buzz Series | Social Media’s Impact on Hair Loss Information
hair lossSocial media is a major source of medical information, including information about hair loss. How reliable is the hair loss material presented on social media, and how does this information impact patients? Those are some of the questions posed by researchers in a study published in the March Journal of Drugs in Dermatology. I interviewed author Raymond Ezzat, third-year medical student at Geor …
hair loss
JDD Buzz Series | Sunscreens: Mechanisms and Safety in Depth
sunscreen[vc_row][vc_column][vc_column_text css=""]Despite decades of educational efforts, there is growing public skepticism over sunscreen’s safety and efficacy. Researchers from Chicago sought to synthesize the current scientific understanding of sunscreen in order to help dermatology clinicians address concerns. The findings are published in the February Journal of Drugs in Dermatology. I intervie …
sunscreen
JDD Buzz Series | Diversity in Melasma Clinical Trials
melasmaUnderrepresentation of patients with skin of color in clinical trials is an issue in medical research, including in research about dermatological conditions. A study in the January Journal of Drugs in Dermatology looked at the diversity of patients enrolled in melasma clinical trials to determine if there are any disparities in representation. I interviewed author Jared Jagdeo, MD, MS, associat …
melasma
JDD Buzz Series | Metformin’s Potential Chemopreventive Effect
metforminA commonly used diabetes medication may help prevent non-melanoma skin cancer. A study in the December Journal of Drugs in Dermatology analyzed whether metformin exposure is associated with a reduced risk of non-melanoma skin cancer. The study also stratified findings by race/ethnicity, which makes it unique among similar research studies. I interviewed author Tiffany Jow Libby, MD, FAAD, FACMS …
metformin